The use of hERG agonist to mitigate the inhibitory effects of drug inhibitors that have been shown to be effective in rescuing defective channel trafficking, in both congenital and acquired forms of LQTS, may therefore constitute a new therapeutic tool. This evidence concerns the gene KCNH2 and familial long QT syndrome.